You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 9,309,234


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,309,234 protect, and when does it expire?

Patent 9,309,234 protects OLINVYK and is included in one NDA.

This patent has fifty-one patent family members in twenty-three countries.

Summary for Patent: 9,309,234
Title:Opioid receptor ligands and methods of using and making same
Abstract: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
Inventor(s): Yamashita; Dennis (Cambridge, MA), Gotchev; Dimitar (Hatboro, PA), Pitis; Philip (North Wales, PA), Chen; Xiao-Tao (Furlong, PA), Liu; Guodong (Jamison, PA), Yuan; Catherine C. K. (King of Prussia, PA)
Assignee: Trevena, Inc. (King of Prussia, PA)
Application Number:14/712,974
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;
Patent landscape, scope, and claims:

United States Patent 9,309,234: A Detailed Analysis of Scope and Claims

Introduction

United States Patent 9,309,234, titled "Opioid receptor ligands and methods of using and making same," was granted on April 12, 2016, to Trevena, Inc. This patent is significant in the field of pharmaceuticals, particularly in the treatment of pain and other conditions through opioid receptor ligands.

Background and Inventors

The patent was invented by a team of researchers including Dennis Yamashita, Dimitar Gotchev, Philip Pitis, Xiao-Tao Chen, Guodong Liu, and Catherine C. K. Yuan. The assignee is Trevena, Inc., a company based in King of Prussia, PA[1][4].

Scope of the Patent

The patent describes compounds that act as opioid receptor ligands. These compounds are designed for the treatment of pain and other conditions associated with opioid receptors. The scope includes the synthesis, use, and application of these compounds in various therapeutic contexts.

Therapeutic Applications

The compounds covered by this patent are intended for use in treating pain, which is a significant area of medical need. The opioid receptor ligands can modulate the activity of opioid receptors, providing potential therapeutic benefits without some of the adverse effects associated with traditional opioids[1][4].

Claims Analysis

The patent includes a series of claims that define the scope of protection for the invented compounds and methods.

Independent Claims

The patent includes independent claims that broadly define the compounds and their uses. These claims are crucial as they set the boundaries of what is protected under the patent. For example, Claim 1 might describe a specific chemical structure of the opioid receptor ligand, while Claim 2 might describe a method of using this ligand for pain treatment[1][4].

Dependent Claims

Dependent claims build upon the independent claims, providing additional specificity and narrowing down the scope. These claims can include variations in the chemical structure, different methods of synthesis, or specific therapeutic applications. The strategic management of these dependent claims is essential to ensure comprehensive protection of the invention[5].

Patent Landscape

Understanding the patent landscape is crucial for assessing the value and impact of this patent.

Related Patents and Applications

This patent is part of a series of related applications and patents filed by Trevena, Inc. It is a continuation of earlier applications, such as application No. 13/964,505, which is now Pat. No. 9,044,469. This indicates a robust and evolving intellectual property strategy by the company[1].

Claim Coverage and Scope Concepts

To fully analyze the patent landscape, it is important to categorize the patents and claims by scope concepts. This approach, as described in patent analytics, helps in identifying gaps and opportunities in the intellectual property portfolio. The Claim Coverage Matrix and Claim Charts can be used to review and analyze the patent coverage, ensuring that the technology intended to be protected is adequately covered[3].

Strategic Claim Management

The management of claims within this patent is critical for maximizing its value.

Optimizing Claim Structure

The initial patent application filing fee covers up to 3 independent claims and a total of 20 claims. Strategically managing these claims to ensure that the full quota is utilized can enhance the patent’s breadth and flexibility. This involves consolidating dependent claims into broader independent claims and adding new dependent claims for every claim that is canceled[5].

Commercial and Defensive Value

Each claim in the patent application can be seen as a unique tool for protecting different facets of the invention. By ensuring that the patent utilizes its full complement of claims, Trevena, Inc. can secure more robust and nuanced protection. This not only enhances the patent’s defensive capabilities but also its value in potential licensing discussions or infringement disputes[5].

Economic and Legal Implications

The economic and legal implications of this patent are significant.

Market Impact

The compounds described in this patent have the potential to address a significant medical need, which could lead to substantial market impact. Effective claim management ensures that the company can protect its innovation comprehensively, thereby maintaining a competitive edge in the market[5].

Legal Considerations

The legal status of the patent is active, indicating that it is currently enforceable. However, the legal landscape around patents is complex, and continuous monitoring and adjustment of claims may be necessary to align with USPTO requirements and to maintain the patent’s validity[4].

Conclusion

United States Patent 9,309,234 is a critical piece of intellectual property for Trevena, Inc., offering significant therapeutic potential in the treatment of pain. The strategic management of its claims, understanding the related patent landscape, and optimizing the claim structure are all essential for maximizing the patent’s value and defensive capabilities.

Key Takeaways

  • Therapeutic Applications: The patent covers opioid receptor ligands for pain treatment.
  • Claims Structure: Includes independent and dependent claims to ensure comprehensive protection.
  • Patent Landscape: Part of a series of related patents and applications.
  • Strategic Claim Management: Utilizing the full quota of claims to enhance patent value.
  • Economic and Legal Implications: Significant market impact and legal considerations.

FAQs

What is the primary therapeutic application of the compounds described in US Patent 9,309,234?

The primary therapeutic application is the treatment of pain through opioid receptor ligands.

How many claims can be included in the initial patent application filing fee in the United States?

The initial patent application filing fee covers up to 3 independent claims and a total of 20 claims.

What is the importance of strategic claim management in patent applications?

Strategic claim management ensures that the patent utilizes its full complement of claims, enhancing its breadth, flexibility, and value.

How can patent analytics help in understanding the patent landscape?

Patent analytics helps in categorizing patents by scope concepts, identifying gaps and opportunities, and reviewing claim coverage through tools like Claim Coverage Matrix and Claim Charts.

What is the current legal status of US Patent 9,309,234?

The patent is currently active, indicating it is enforceable.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,309,234

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 RX Yes Yes 9,309,234 ⤷  Subscribe Y Y MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION ⤷  Subscribe
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 RX Yes Yes 9,309,234 ⤷  Subscribe Y Y MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION ⤷  Subscribe
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 RX Yes Yes 9,309,234 ⤷  Subscribe Y Y MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.